Loading...
Docoh

Blueprint Medicines (BPMC)

39 patents

Page 2 of 2
Utility
Inhibitors of the fibroblast growth factor receptor
28 Dec 20
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
Filed: 18 Feb 19
Utility
PIK3C2G fusions
28 Dec 20
The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins.
Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
Filed: 29 Jul 14
Utility
Compositions and methods for treating KIT- and PDGFRA-mediated diseases
9 Nov 20
Thomas A. Dineen
Filed: 7 Apr 20
Utility
Substituted Pyrrolopyridines As Inhibitors of Activin Receptor-like Kinase
21 Oct 20
Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
Filed: 17 Oct 18
Utility
Compositions useful for treating disorders related to kit
19 Oct 20
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Kevin J. Wilson
Filed: 6 May 18
Utility
Compositions and Methods for Treating Kit- and Pdgfra-mediated Diseases
14 Oct 20
Thomas A. Dineen, Joseph L. Kim, Timothy Guzi
Filed: 7 Apr 20
Utility
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
14 Sep 20
Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
Filed: 19 Dec 18
Utility
PRKC Fusions
10 Jun 20
The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides.
Nicolas Stransky, Joseph L. Kim
Filed: 15 Jul 19
Utility
RAF1 Fusions
3 Jun 20
The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides.
Nicolas Stransky, Joseph L. Kim
Filed: 15 Jul 19
Utility
Inhibitors of activin receptor-like kinase
1 Jun 20
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Kevin J. Wilson, Josh Waetzig
Filed: 4 Mar 19
Utility
PIK3CA fusions
1 Jun 20
The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions.
Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
Filed: 26 Feb 19
Utility
Inhibitors of the Fibroblast Growth Factor Receptor
8 Apr 20
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
Filed: 18 Feb 19
Utility
Inhibitors of RET
9 Mar 20
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 19 Jul 18
Utility
Inhibitors of Activin Receptor-like Kinase
29 Jan 20
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Kevin J. Wilson, Josh Waetzig
Filed: 4 Mar 19
Utility
PYRROLO[1,2-B]PYRIDAZINE Compounds and Compositions Useful for Treating Disorders Related to Kit and PDGFR
22 Jan 20
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
Filed: 28 Mar 18
Utility
NTRK2 Fusions
25 Dec 19
The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fosion proteins, and fragments of those genes and polypeptides.
Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
Filed: 31 Jul 19
Utility
Compounds and Compositions Useful for Treating Disorders Related to NTRK
18 Dec 19
This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
Filed: 30 Jul 19
Utility
2-(PYRIDIN-3-YL)-PYRIMIDINE Derivatives As Ret Inhibitors
27 Nov 19
Natasja BROOIJMANS, Lucian V. DIPIETRO, Paul E. FLEMING, Joseph L. KIM, Steven Mark WENGLOWSKY, Yulian ZHANG
Filed: 19 Dec 18
Utility
Inhibitors of the Fibroblast Growth Factor Receptor
27 Nov 19
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
Neil BIFULCO, JR., Natasja BROOIJMANS, Brian L. HODOUS, Joseph L. KIM, Chandrasekhar V. MIDUTURU
Filed: 20 Dec 18
Patents are sorted by USPTO publication date, most recent first